Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Jun;44(6):2755-2758.
doi: 10.21873/anticanres.17084.

Neoadjuvant Treatment for a cT4cN+ HER2+ Breast Cancer: Case Report of a Therapeutic Success

Marco Gunnellini  1 , Antonio Tornincasa  2 , Michele Montedoro  2 , Andrea Caprodossi  3 , Enrico Prosperi  4 , Manola Peverini  3 , Alessandra Mariottini Sarti  3 , Silvia Aiuti  5 , Tommaso Morini  3
Affiliations
Case Reports

Neoadjuvant Treatment for a cT4cN+ HER2+ Breast Cancer: Case Report of a Therapeutic Success

Marco Gunnellini et al. Anticancer Res. 2024 Jun.

Abstract

Background: HER2 positive disease accounts for 15-20% of early breast cancer. Achieving a pathological complete response after neoadjuvant chemotherapy (NACT) improves prognosis and decreases risk of recurrence.

Case report: Our case report aimed to highlight an emblematic clinical success and benefit of NACT with the addition of pertuzumab to the standard trastuzumab/taxane/anthracycline combination in a patient with a 9 cm breast neoplasm and extensive lymph node involvement (>4 pathological lymph nodes).

Conclusion: Achieving a complete pathological response with NACT, should be the main goal, especially in patients with triple negative and HER2 positive breast cancer.

Keywords: Breast cancer; HER2+; neoadjuvant.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources